ID   KKU-M139/GEM
AC   CVCL_HF57
DR   Wikidata; Q54900006
RX   PubMed=25998688;
CC   Population: Southeast Asian; Thai.
CC   Doubling time: 20.32 +- 2.79 hours (PubMed=25998688).
CC   Selected for resistance to: ChEBI; CHEBI_175901; Gemcitabine (Gemzar).
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M259 ! KKU-M139
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 19-12-24; Version: 6
//
RX   PubMed=25998688; DOI=10.3892/ijo.2015.3019;
RA   Wattanawongdon W., Hahnvajanawong C., Namwat N., Kanchanawat S.,
RA   Boonmars T., Jearanaikoon P., Leelayuwat C., Techasen A., Seubwai W.;
RT   "Establishment and characterization of gemcitabine-resistant human
RT   cholangiocarcinoma cell lines with multidrug resistance and enhanced
RT   invasiveness.";
RL   Int. J. Oncol. 47:398-410(2015).
//